MUSC

ThinkAndor, an AI-first platform, transforms emergency care at the Medical University of South Carolina

Retrieved on: 
Donnerstag, Mai 2, 2024
Nexus, Emergency department, Medical school, Bed, Heart, MUSC, Triage, Partnership, Artificial intelligence, Observation, Documentation, Patient, ATA, Emergency medicine, ED, Nursing

The demand for emergency care continues to rise, leading to overcrowding and excessive wait times.

Key Points: 
  • The demand for emergency care continues to rise, leading to overcrowding and excessive wait times.
  • Health systems can optimize emergency care delivery by integrating AI-powered ThinkAndor Virtual Rounding and virtual triage capabilities into traditional ED workflows.
  • Even during peak demand when the hospital is at- or overcapacity, the virtual care we are delivering through ThinkAndor ensures optimal outcomes," said Morsal Tahouni, M.D., assistant professor and medical director of Emergency Medicine, Department of Emergency Medicine, Medical University of South Carolina.
  • Visit Andor Health at ATA Nexus 2024 booth 619 to learn why ThinkAndor is the leading AI-first virtual care collaboration platform.

Magnus Medical Announces Commercial Launch of Groundbreaking SAINT Neuromodulation System

Retrieved on: 
Dienstag, April 30, 2024
Mental Health, Health, FDA, Medical Devices, Neurology, Health Technology, General Health, SAINT, University, CMS, DSM-IV codes, MUSC, American Medical Association, Medicine, Depression, Psychiatry, Patient, CPT, NTAP, Medicare, MRI, CSO, Magnetic resonance imaging, Multimedia, MDD, TMS, Pharmaceutical industry

Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced the commercial launch of the SAINT® neuromodulation system, a groundbreaking, rapid-acting therapy for treatment-resistant major depressive disorder (MDD).

Key Points: 
  • Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced the commercial launch of the SAINT® neuromodulation system, a groundbreaking, rapid-acting therapy for treatment-resistant major depressive disorder (MDD).
  • View the full release here: https://www.businesswire.com/news/home/20240430113478/en/
    The commercially available SAINT® neuromodulation system from Magnus Medical provides a new form of individualized neurostimulation therapy for treatment-resistant major depression in adults who have failed to achieve satisfactory improvement from prior antidepressant medications.
  • The American Medical Association (AMA) issued new Category III Current Procedural Terminology (CPT) codes for targeted, accelerated iTBS for depression, encompassing the SAINT neuromodulation system, effective July 1, 2024.
  • Magnus Medical expects to have selective insurance coverage in both the hospital inpatient and outpatient setting and the physician’s office.

AMPEL BioSolutions Selected as Member of ARPA-H Customer Experience Hub Spoke Network

Retrieved on: 
Dienstag, April 23, 2024
Mayo Clinic, DARPA, Providence Healthcare, Inflammation, United, Lupus, Capital, Blood, ARPANET, Partnering, Health, Cleveland Clinic, MUSC, Customer experience, Nation, University, Autoimmunity, Disease, Duke, UCSF, ARPA, Gene expression, QuidelOrtho, Mass General Brigham, Clinical trial, Medicine, Biotechnology

CHARLOTTESVILLE, Va., April 23, 2024 /PRNewswire/ -- AMPEL BioSolutions has been selected as a member - or "spoke" - of the Customer Experience Hub of ARPANET-H , a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H) .

Key Points: 
  • CHARLOTTESVILLE, Va., April 23, 2024 /PRNewswire/ -- AMPEL BioSolutions has been selected as a member - or "spoke" - of the Customer Experience Hub of ARPANET-H , a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H) .
  • AMPEL's ARPA-H spoke election highlights one-of-a-kind Precision Health tests that predict inflammation and abnormal drug targets from gene expression utilizing "explainable AI" (xAI).
  • Other corporate Hub Spoke members include Verily, Datavant, Velsara, QuidelOrtho and Biolabs.
  • As a Customer Experience spoke, AMPEL has access to funding and flexible contracting for expeditious product execution and scaling.

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Retrieved on: 
Dienstag, März 12, 2024
Gait, Walking, Patient, Stroke, Rehabilitation, HSDT, Doctor of Philosophy, Survivor, Medical school, MUSC, Pons, Pharmaceutical industry

NEWTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the initiation of an open-label study for its registrational program in stroke. The program was established based on encouraging early trial results as well as real-world evidence from Canada, where PoNS is already authorized for treatment of stroke, and aims to establish the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”), delivered using PoNS Therapy®, on gait and dynamic balance in chronic stroke survivors.

Key Points: 
  • -- Results will support efforts to achieve U.S. authorization under PoNS’s breakthrough designation for stroke --
    NEWTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the initiation of an open-label study for its registrational program in stroke.
  • Under the direction of Mark Bowden, PT, PhD, Brooks Rehabilitation (“Brooks Rehabilitation”) will be the first site to enroll patients.
  • Brooks Rehabilitation is already a participant site to the Company’s ongoing investigator-initiated, placebo-controlled study in stroke, led by Dr. Steven Kautz at the Medical University of South Carolina (“MUSC”).
  • “PoNS Therapy has the potential to meaningfully improve the lives of over five million stroke patients affected by walking and balance disability.

The Medical University of South Carolina and Flatiron Health Announce Collaboration to Drive More Standardized, Efficient, and Effective Cancer Care

Retrieved on: 
Mittwoch, März 13, 2024
Research, Technology, Clinical Trials, Health Technology, University, Health, Science, Education, Oncology, Artificial Intelligence, Evidence-based medicine, Associate, Patient, NCCN, Assist, MD, MHS, Medical school, Flatiron, MUSC, Division, Clinical Oncology, Hematology, Medicine, Nursing

The collaboration between Flatiron Health and MUSC will equip clinicians with advanced cancer care insights from Flatiron Assist, an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways, and clinical research at the point of care.

Key Points: 
  • The collaboration between Flatiron Health and MUSC will equip clinicians with advanced cancer care insights from Flatiron Assist, an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways, and clinical research at the point of care.
  • “Partnering with the Medical University of South Carolina’s Hollings Cancer Center, a market-leading cancer care provider, is an incredible opportunity to accelerate our shared vision for the delivery of more standardized, efficient, and effective cancer care,” said James Hamrick, MD, Vice President of Clinical Oncology at Flatiron Health.
  • Flatiron Assist users also adopt novel therapies an average of 59 days sooner than non-Flatiron Assist users ensuring higher quality care.
  • “This project will reduce variability in cancer treatment while increasing the quality of cancer care provided across the state of South Carolina.”

VPL onboards seven new health orgs, reaffirms commitment to customer satisfaction

Retrieved on: 
Mittwoch, März 6, 2024
Riverside Medical Center, Allina Health, Medical school, MUSC, VPL, Hospital

COLUMBUS, Ohio, March 6, 2024 /PRNewswire-PRWeb/ -- Clinical supply chain management provider VPL onboarded over seven new health organizations in 2023, including Allina Health, Anderson Hospital, Medical University of South Carolina (MUSC), Riverside Medical Center, Rocky Mountain Vital Care, Sarasota Specialty Rx and Innoterix Labs.

Key Points: 
  • Clinical supply chain management provider VPL onboarded over seven new health organizations in 2023, including Allina Health, Anderson Hospital, Medical University of South Carolina (MUSC), Riverside Medical Center, Rocky Mountain Vital Care, Sarasota Specialty Rx and Innoterix Labs.
  • COLUMBUS, Ohio, March 6, 2024 /PRNewswire-PRWeb/ -- Clinical supply chain management provider VPL onboarded over seven new health organizations in 2023, including Allina Health, Anderson Hospital, Medical University of South Carolina (MUSC), Riverside Medical Center, Rocky Mountain Vital Care, Sarasota Specialty Rx and Innoterix Labs.
  • The healthcare landscape is rapidly evolving, and health systems are increasingly recognizing the importance of strategic conversations and scalable solutions in clinical supply chain management.
  • To stay competitive in this evolving landscape, VPL announced their commitment to broadening the scope of value they provide.

Medical University of South Carolina Joins the Guardian Research Network

Retrieved on: 
Mittwoch, Februar 21, 2024
Education, GRN, Health, Health Affairs, RWD, Benchmarking, Medical school, Research, MUSC, Patient, Cancer, Management

SPARTANBURG, S.C., Feb. 21, 2024 /PRNewswire/ -- Guardian Research Network, Inc. (GRN) announced today that the Medical University of South Carolina (MUSC), the only comprehensive academic health system in the state, joined its nationwide consortium of healthcare organizations as the first academic medical center member. This strategic collaboration will augment GRN's mission to expedite cure discovery and care improvements, as well as MUSC's mission to fuel research, education, and innovative care for improved patient outcomes.

Key Points: 
  • SPARTANBURG, S.C., Feb. 21, 2024 /PRNewswire/ -- Guardian Research Network, Inc. (GRN) announced today that the Medical University of South Carolina (MUSC), the only comprehensive academic health system in the state, joined its nationwide consortium of healthcare organizations as the first academic medical center member.
  • This strategic collaboration will augment GRN's mission to expedite cure discovery and care improvements, as well as MUSC's mission to fuel research, education, and innovative care for improved patient outcomes.
  • "Adding a prestigious academic health system elevates the entire GRN network," comments Bruce Holstien, GRN's chief executive officer.
  • "Their innovative leadership, clinical excellence and research expertise will add another dimension to our network as we all work together to create the next generation of care."

QuicksortRx Hits $100 Million Saved for Health Systems

Retrieved on: 
Mittwoch, Januar 31, 2024
Medical school, Growth, Yantis, Texas, Entrepreneurship, Health, MUSC, Software, Invention, Pharmacist, Hospital

Founded by pharmacists and technologists from the Medical University of South Carolina (MUSC), QuicksortRx empowers health systems to instantly assess medication price, availability, and purchasing trends across multiple facilities.

Key Points: 
  • Founded by pharmacists and technologists from the Medical University of South Carolina (MUSC), QuicksortRx empowers health systems to instantly assess medication price, availability, and purchasing trends across multiple facilities.
  • The $100 million figure represents realized savings tracked by health systems using QuicksortRx to identify and operationalize changes in their medication procurement.
  • It's difficult to put into words what it means to know we have enabled non-profit health systems to redeploy over $100 million into initiatives that benefit their communities.
  • Thank you to these health systems for rolling up your sleeves with us and putting in the work.

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

Retrieved on: 
Donnerstag, Januar 11, 2024
Pons, Helios, Patient, Multiple sclerosis, MUSC, Medical school, Gait, HSDT, Partnership, Walking, Stroke, Survivor, Rehabilitation, Doctor of Philosophy

NEWTOWN, Pa., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the expansion of the registrational program with the addition of Brooks Rehabilitation Hospital (“Brooks Rehabilitation”). The program, structured on the basis of encouraging results from an early trial as well as real-world evidence from Canada, where PoNS is already authorized for treatment of stroke, focuses on establishing the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”), delivered using PoNS Therapy™, on gait and dynamic balance in chronic stroke survivors. Brooks Rehabilitation will participate as an adjunct site, under the direction of Dr. Mark Bowden, PT, PhD, Vice President of Clinical Integration and Research, to the ongoing investigator-initiated, placebo-controlled study in stroke, led by Dr. Steven Kautz at the Medical University of South Carolina (“MUSC”). Dr. Bowden will also take part in additional clinical activities that, when combined with the randomized controlled study, aim to bring the total number of subjects enrolled in the clinical program to approximately 100.

Key Points: 
  • Dr. Bowden will also take part in additional clinical activities that, when combined with the randomized controlled study, aim to bring the total number of subjects enrolled in the clinical program to approximately 100.
  • “The participation of Brooks Rehabilitation marks an important step in the implementation of our clinical program under breakthrough designation for stroke.
  • Dr. Bowden, with his longstanding leadership and contribution to the field of neurorehabilitation for stroke, brings the expertise needed to execute our registrational program.
  • Starting in January 2024, Dr. Bowden anticipates enrolling approximately 40 participants to the development program at Brooks Rehabilitation and expects full enrollment by the end of the year.

K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

Retrieved on: 
Mittwoch, November 15, 2023
NDA, Multiple myeloma, Pharmacia, Pfizer, Bristol Myers Squibb, Senior, Therapy, Clinical trial, MUSC, Patient, Communication, Medicine, Clinical research, Prostate cancer, Schering-Plough, Kite Pharma, MD, Drug discovery, Allogeneic processed thymus tissue, BMS, Doctor of Philosophy, Health, Drug, BCMA, Lava, ChromeOS, Translational medicine, GSK plc, Medical imaging, Pharmaceutical industry, Management, Celgene, Temozolomide, K36

CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams. Dr. Winograd joins K36 with a wealth of experience and a remarkable track record of bringing innovative medicines for hematological and solid tumor disease treatments to patients.

Key Points: 
  • Additional industry veterans recruited to strengthen clinical, translational medicine and preclinical teams
    CAMBRIDGE, Mass., Nov. 15, 2023 /PRNewswire/ -- K36 Therapeutics, Inc .
  • ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams.
  • "Recruiting a leader with Dr. Winograd's expertise, reputation and track record of advancing transformative therapies validates the potential opportunity that KTX-1001 will deliver," said Terry Connolly, PhD, President and Chief Executive Officer of K36.
  • Most recently, Dr. Winograd was the Chief Medical Officer at Lava Therapeutics B.V. Dr. Winograd brings over 30 years of industry experience to K36, and will lead clinical development, translational medicine, regulatory affairs, and medical affairs.